AU2011252127B2 - Process for the preparation of insulin-zinc complexes - Google Patents

Process for the preparation of insulin-zinc complexes Download PDF

Info

Publication number
AU2011252127B2
AU2011252127B2 AU2011252127A AU2011252127A AU2011252127B2 AU 2011252127 B2 AU2011252127 B2 AU 2011252127B2 AU 2011252127 A AU2011252127 A AU 2011252127A AU 2011252127 A AU2011252127 A AU 2011252127A AU 2011252127 B2 AU2011252127 B2 AU 2011252127B2
Authority
AU
Australia
Prior art keywords
insulin
cooh
chain
process according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011252127A
Other languages
English (en)
Other versions
AU2011252127A1 (en
Inventor
Lene Andresen
Rosa Rebecca Erritzoe Hansen
Per Jeppesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2011252127A1 publication Critical patent/AU2011252127A1/en
Application granted granted Critical
Publication of AU2011252127B2 publication Critical patent/AU2011252127B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2011252127A 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes Ceased AU2011252127B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10162368 2010-05-10
EP10162368.4 2010-05-10
US33349710P 2010-05-11 2010-05-11
US61/333,497 2010-05-11
PCT/EP2011/057388 WO2011141407A1 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Publications (2)

Publication Number Publication Date
AU2011252127A1 AU2011252127A1 (en) 2012-11-01
AU2011252127B2 true AU2011252127B2 (en) 2014-02-20

Family

ID=42732779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011252127A Ceased AU2011252127B2 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Country Status (12)

Country Link
US (5) US20130143803A1 (enExample)
EP (1) EP2569002B1 (enExample)
JP (2) JP6249773B2 (enExample)
KR (2) KR20130092972A (enExample)
CN (2) CN107029212A (enExample)
AU (1) AU2011252127B2 (enExample)
BR (1) BR112012028766A2 (enExample)
CA (1) CA2795091A1 (enExample)
ES (1) ES2612468T3 (enExample)
MX (1) MX2012012943A (enExample)
RU (1) RU2572214C2 (enExample)
WO (1) WO2011141407A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
CN105636979B (zh) * 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
WO2019110797A1 (fr) * 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020008129A (es) * 2018-02-01 2020-09-18 Jiangsu Hengrui Medicine Co Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma.
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
BR112021011156A2 (pt) 2018-12-11 2021-10-26 Sanofi Conjugados de insulina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US20090312236A1 (en) * 2008-06-13 2009-12-17 John Michael Beals Pegylated insulin lispro compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) * 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
EP0792290B1 (en) * 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP2264066A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
PT1969004E (pt) * 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US20090312236A1 (en) * 2008-06-13 2009-12-17 John Michael Beals Pegylated insulin lispro compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Also Published As

Publication number Publication date
BR112012028766A2 (pt) 2017-06-13
CN102883743A (zh) 2013-01-16
KR20130092972A (ko) 2013-08-21
EP2569002B1 (en) 2016-10-26
US20150250857A1 (en) 2015-09-10
ES2612468T3 (es) 2017-05-17
AU2011252127A1 (en) 2012-11-01
US20210060132A1 (en) 2021-03-04
US20170165327A1 (en) 2017-06-15
KR20160105979A (ko) 2016-09-08
RU2012148821A (ru) 2014-06-20
EP2569002A1 (en) 2013-03-20
MX2012012943A (es) 2012-11-29
JP2013526501A (ja) 2013-06-24
US20130143803A1 (en) 2013-06-06
CA2795091A1 (en) 2011-11-17
CN107029212A (zh) 2017-08-11
US20240307503A1 (en) 2024-09-19
JP2017203042A (ja) 2017-11-16
RU2572214C2 (ru) 2015-12-27
JP6249773B2 (ja) 2017-12-20
WO2011141407A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
AU2011252127B2 (en) Process for the preparation of insulin-zinc complexes
US9603904B2 (en) Treating diabetes melitus using insulin injections with less than daily injection frequency
ES2360505T3 (es) Preparados de insulina libre de zinc o con bajo contenido en cinc con estabilidad mejorada.
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
US20130261051A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
CN102665676B (zh) 非共价结合的白蛋白和酰化胰岛素的药物溶液
US20180125946A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
IT8223018A1 (it) Formulazioni farmaceutiche comprendenti insulina, c-peptide e pro-insulina umani

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired